Holen Sie sich die Stockscreener-App
6.18
0.16%
-0.01
Handel nachbörslich:
6.18
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.19
Offen:
$6.12
24-Stunden-Volumen:
734.42K
Relative Volume:
0.47
Marktkapitalisierung:
$583.69M
Einnahmen:
$829.00M
Nettoeinkommen (Verlust:
$-399.90M
KGV:
-1.4319
EPS:
-4.3159
Netto-Cashflow:
$-23.20M
1W Leistung:
+6.00%
1M Leistung:
+41.10%
6M Leistung:
+4.39%
1J Leistung:
+28.22%
1-Tages-Spanne:
$6.06
$6.235
1-Wochen-Bereich:
$5.67
$6.43
52-Wochen-Spanne:
$3.53
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.18 | 584.63M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
ETFs Investing in Myriad Genetics, Inc. Stocks - TradingView
Is This the Right Time to Hold MYGN Stock in Your Portfolio? - Yahoo Finance Singapore
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - qz.com
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Announces Target Price $4 - Moomoo
Myriad Genetics (MYGN) Q4 2024 earnings summary - Quartr
Myriad Genetics (MYGN) Proxy filing Summary - Quartr
(MYGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Myriad Genetics (MYGN) Surges 3.5%: Approaching Resistance at $6.51ADD Alert - dars.gov.et
Myriad Genetics Q1 2026 Earnings: EPS Miss Clouds Diagnostic Growth OutlookGross Profit Margin - dars.gov.et
Meta-analysis confirms Myriad's Prolaris test e... - Pluang
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer - 富途牛牛
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer - Yahoo Finance
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS - BioSpace
Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa
MYGNMyriad Genetics Inc Latest SEC Filings - Finviz
Sera Prognostics adds former Myriad Genetics CEO to board - Investing.com
Sera Prognostics adds former Myriad CEO Mark Capone to board - Stock Titan
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance
(MYGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Price to sales forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Price to book forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Myriad Genetics, Inc. Actuals & Estimates (NASDAQ:MYGN) - TradingView
897518 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Price to sales forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – LS:897518 - TradingView
MYGN Stock Price, Quote & Chart - ChartMill
MYGN Forecast — Price Target — Prediction for 2027 - TradingView
Myriad Genetics, Inc. Actuals & Estimates (FWB:MYD) - TradingView
Myriad Genetics clears analyst hurdle, shares steady on NASDAQ - Ad Hoc News
MYD Forecast — Price Target — Prediction for 2027 - TradingView
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today - Yahoo Finance
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication - Sahm
Director at Myriad Genetics (MYGN) reports 195,507-share Common Stock stake - Stock Titan
Myriad Genetics expands cancer detection test availability By Investing.com - Investing.com Australia
Form 8K Myriad Genetics Inc For: 23 June By Investing.com - Investing.com Australia
MYGN PE Ratio & Valuation, Is MYGN Overvalued - Intellectia AI
Myriad Genetics expands cancer detection test availability - Investing.com
Myriad Genetics director Daniel Skovronsky resigns from board By Investing.com - Investing.com Australia
Myriad Genetics director Daniel Skovronsky resigns from board - Investing.com UK
MYRIAD GENETICS, INC. 8-K Filing: Key Company Information and SEC Compliance Details for June 2026 - Minichart
Myriad widens cancer test access as breast study bolsters its case - Stock Titan
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):